Eris Lifesciences is set to acquire the remaining 30% stake in its subsidiary, Swiss Parenterals Limited, for ₹423.30 crore. The consideration will be discharged through the issuance of Eris Lifesciences equity shares on a preferential basis. The move aims to fully consolidate operations, enhance synergy, and achieve complete managerial control over Swiss Parenterals. The transaction is expected to close tentatively before March 31, 2026.
Swiss Parenterals Acquisition
Eris Lifesciences has announced the acquisition of the remaining 30% share capital of Swiss Parenterals Limited (“Swiss”). This acquisition will make Swiss Parenterals a wholly owned subsidiary of Eris Lifesciences. The announcement was made on November 24, 2025, following a Board of Directors meeting.
Transaction Details
The acquisition will be completed at a cost of ₹423.30 crore. The consideration will be discharged by Eris Lifesciences through the issuance of up to 2,306,372 equity shares of the company on a preferential basis. This will be issued to Mr. Naishadh Shah, a Director of Swiss Parenterals.
Strategic Rationale
The primary objective of this acquisition is to fully consolidate its position, enhance operational synergy, and strengthen its long-term strategic presence. By acquiring 100% ownership of Swiss, Eris Lifesciences expects to achieve complete managerial control, enable full financial consolidation, improve cost efficiencies, streamline governance, and contribute to enhanced shareholder value.
Swiss Parenterals Overview
Swiss Parenterals is involved in the Parenterals business. Incorporated on February 4, 1997, Swiss Parenterals has a strong presence in ~80+ countries. The turnover for the last three financial years is as follows:
* FY 2022-23: ₹220.80 Crores
* FY 2023-24: ₹282.97 Crores
* FY 2024-25: ₹351.11 Crores
Preferential Allotment
As part of the acquisition, Eris Lifesciences will issue up to 2,306,372 fully paid-up equity shares at a price of ₹1,835.35 per share to Mr. Naishadh Shah. This price has been determined based on an independent valuation report dated November 24, 2025.
Source: BSE
